YK

Yogesh Kapoor

Active Director Director DIN 10040388
DIN 10040388 First appointment Feb 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2023
Shareholding value •••• Premium profile

About Yogesh Kapoor

Data last updated:

Yogesh Kapoor is a Director at Venor Pharma Limited (since 2023). The company operates in Pharma. Venor Pharma Limited reported revenue of ₹106 Cr (FY 2025).

DIN 10040388
Primary Designation Director
Industry Pharma
First Appointment 08 Feb 2023
Oldest Company Age 13 yrs
Largest company Venor Pharma Limited · ₹106 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Venor Pharma Limited U74900DL2013PLC251565
Director08 Feb 20232013₹106 Cr (FY 2025)Active

Board colleagues of Yogesh Kapoor

Directorship timeline

Open interactive timeline →
Venor Pharma Limited
Premium access

Shareholding and investment profile for Yogesh Kapoor

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Yogesh Kapoor

Yogesh Kapoor currently holds 1 directorship: Venor Pharma Limited (Director, since 08 Feb 2023, revenue ₹106 Cr (FY 2025)).

Yogesh Kapoor was first appointed on 08 Feb 2023 as Director at Venor Pharma Limited.

The current boards of Yogesh Kapoor's companies include Ritesh Khetarpal (Venor Pharma Limited), Savita Verma (Venor Pharma Limited), Shivam Verma (Venor Pharma Limited), Shubham Verma (Venor Pharma Limited), Vishwas Verma (Venor Pharma Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available